Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems, Inc. (NASDAQ: KRMD) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on large-volume subcutaneous infusion solutions. News about KORU Medical frequently centers on its Freedom Syringe Infusion System, financial performance, regulatory milestones, and collaborations with biopharmaceutical partners.
Investors following KRMD news can expect regular updates on quarterly and annual financial results, including net revenue trends, core business performance, and contributions from Pharma Services and Clinical Trials. The company often provides revenue guidance and discusses metrics such as gross margin and cash position in its earnings-related press releases, which are also referenced in Form 8-K filings.
KORU Medical’s news flow also highlights regulatory and clinical developments. This includes FDA 510(k) submissions for the Freedom System to be used with specific biologic drugs, such as rare disease therapies and oncology biologics like PHESGO for HER2+ breast cancer. The company reports clinical and real-world evidence, including multicenter evaluations comparing the FreedomEdge Infusion System with manual push techniques in oncology and immunology settings, focusing on nurse satisfaction, patient comfort, and workflow efficiency.
Another key news category involves strategic collaborations and development agreements with pharmaceutical and medical technology partners. Examples include agreements to develop next-generation subcutaneous immunoglobulin infusion systems and to integrate the FreedomEdge pump into wearable infusion platforms for targeted antibiotic delivery in periprosthetic joint infection.
In addition, KORU Medical issues announcements about leadership appointments, equity awards, and participation in investor conferences, providing insight into its management priorities and engagement with the investment community. For ongoing coverage of KRMD, this news page aggregates company press releases and related updates so readers can monitor financial disclosures, regulatory progress, and partnership activity over time.
KORU Medical Systems (NASDAQ: KRMD) has announced an upcoming investor day designed to update stakeholders on its strategic plan. The event is set for December 9, 2021, at 10:00 AM EST. Interested parties can access the live and archived webcast on the company's website.
KORU Medical specializes in developing innovative home infusion solutions, including the FREEDOM Syringe Infusion System, which enhances patient quality of life.
KORU Medical Systems (NASDAQ: KRMD) reported third-quarter 2021 financial results, achieving net revenue of $6.0 million, a 9% sequential increase from Q2 2021, highlighting three consecutive quarters of growth. Compared to Q3 2020, net revenue decreased slightly by 0.7%. Gross margin declined to 57.9% from 64.8% due to manufacturing transition delays and material scrap. Operating expenses rose to $4.8 million from $3.6 million, influenced by strategic initiatives. The company reported a net loss of $1.1 million, or $(0.02) per diluted share.
KORU Medical Systems (NASDAQ: KRMD) has received FDA 510(k) clearance for its FreedomEdge® infusion pump, making it the sole device authorized for administering Hizentra® prefilled syringes. Hizentra® is the leading subcutaneous immunoglobulin product with a prefilled syringe option, enhancing patient comfort and convenience. The clearance positions KORU Medical as a leader in home delivery subcutaneous immunoglobulin therapy.
KORU Medical Systems (NASDAQ: KRMD) is set to participate in two significant healthcare conferences. The company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 11:00 AM EST. Additionally, management will engage in 1x1 investor meetings at the 33rd Annual Piper Sandler Healthcare Conference on December 1, 2021, and a pre-recorded fireside chat available from November 22. Interested parties can access the live broadcast through KORU Medical’s investor page.
KORU Medical Systems (NASDAQ: KRMD) has announced a collaboration with Gilero, a medical device design and manufacturing company, aimed at enhancing its home infusion product line. This partnership focuses on the advancement of large-volume subcutaneous infusion technology, allowing KORU Medical to innovate and expand its offerings in the growing home infusion market. The collaboration is expected to leverage Gilero's expertise in drug delivery systems to improve patient comfort and convenience in infusion processes.
KORU Medical Systems (NASDAQ: KRMD) announced the appointments of Rob Cannon as Vice President of Sales and Brian Hertzog as Vice President of BioPharma Business Development. Cannon will focus on U.S. sales and enhancing subcutaneous therapy penetration, while Hertzog will drive biopharmaceutical business development and new drug integration. CEO Linda Tharby emphasized the company's growth potential and expertise in large-volume subcutaneous infusion solutions, backed by FDA and CE regulatory clearances. This leadership expansion aims to accelerate growth and meet the significant unmet needs in the biopharmaceutical market.
KORU Medical Systems (NASDAQ: KRMD) will report its third quarter 2021 financial results on November 10, 2021. Management will host a conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can access the call via designated phone numbers based on location or via the company's Investor section. The archived webcast will be available for six months post-event, allowing stakeholders to stay informed about KORU Medical's performance and updates.
Repro Med Systems, Inc., operating as KORU Medical Systems (NASDAQ: KRMD), announced the appointment of Chris Pazdan as Vice President of Quality Assurance and Regulatory Affairs. Mr. Pazdan brings over 16 years of experience from notable companies such as Hillrom and Abbott Laboratories. His expertise in quality and regulatory strategy aims to strengthen KORU Medical's Quality Management System to meet global standards. CEO Linda Tharby emphasized Mr. Pazdan's strategic and operational skills as key assets for the company's growth in meeting biopharmaceutical customer needs.
KORU Medical Systems (NASDAQ: KRMD) reported second-quarter 2021 results with net revenue of $5.5 million, reflecting a 28.3% decline year-over-year but a 2% sequential increase. The gross margin was 58.1%, down 5.6 percentage points from last year, influenced by lower volumes. The company reported a net loss of $1.1 million or $(0.03) per diluted share, unchanged from Q2 2020. Despite these challenges, CEO Linda Tharby noted a rebound in the subcutaneous immunoglobulin market and a focus on growth strategies for their SCIg therapy franchise.
KORU Medical Systems (NASDAQ: KRMD) will participate in Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 3:00 PM EDT. The event highlights the company’s focus on developing specialty infusion solutions aimed at improving patient quality of life.
Management's presentation can be accessed live or in archive for six months via the Investors section of KORU Medical’s website.